Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma,
Bristol-Myers Squibb is getting closer to offering a subcutaneous version of its cancer immunotherapy Opdivo to patients after it matched the current intravenous formulati
The combination of Bristol-Myers Squibb’s Opdivo and Yervoy cancer immunotherapies is on track for approval as a first-line therapy for patients with a particular form of
Shares in US biotech Cytokinetics have popped after a report that its aficamten drug improved symptoms in people with a rare and progressive form of heart disease.
Bristol-Myers Squibb is having a busy holiday period, signing a $4.1 billion deal to acquire cancer drug developer RayzeBio – its second multibillion-dollar M&A deal i
Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approxim
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company